Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on North Dakota Healthcare Newswire.
Press releases published on July 3, 2025
Remote Pharmacy Releases 2025 Availability Update on GLP-1 Weight Loss Solutions and Consumer Interest in Semaglutide & Tirzepatide
GlobeNewswire
·
July 3, 2025
Bowling Green, July 03, 2025 (GLOBE NEWSWIRE) -- Section 1 – Introduction In 2025, the discourse surrounding prescription weight loss treatments is gaining momentum, fueled by increasing public awareness of GLP-1 receptor agonists, such as semaglutide and …
Theratechnologies to Announce Second Quarter 2025 Financial Results
GlobeNewswire
·
July 3, 2025
MONTREAL, July 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced the Company will report financial results for its second …
Theratechnologies annoncera ses résultats financiers du deuxième trimestre de l’exercice financier de 2025
GlobeNewswire
·
July 3, 2025
MONTRÉAL, 03 juill. 2025 (GLOBE NEWSWIRE) -- Theratechnologies inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique au stade commercial, annonce aujourd’hui que la Société dévoilera ses résultats …
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
July 3, 2025
BEDFORD, Mass., July 03, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on July 1, …
Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
July 3, 2025
RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for …
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
July 3, 2025
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced …
Sienna Announces Second Quarter 2025 Results Release Date and Conference Call
GlobeNewswire
·
July 3, 2025
MARKHAM, Ontario, July 03, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) announced that it will report its 2025 second quarter results after market close on Tuesday, August 12, 2025. Nitin Jain, President and …
Merit Medical Systems To Announce Second Quarter 2025 Results On July 30, 2025
GlobeNewswire
·
July 3, 2025
SOUTH JORDAN, Utah, July 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended June 30, …
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
July 3, 2025
BRISBANE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards …
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
July 3, 2025
WESTLAKE VILLAGE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an …
Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines
GlobeNewswire
·
July 3, 2025
BOSTON, July 03, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the publication of groundbreaking new discoveries …
2024 Packaging Research Review: Trends That Will Shape the Future
GlobeNewswire
·
July 3, 2025
Boston, July 03, 2025 (GLOBE NEWSWIRE) -- BCC Research announces the release of its “2024 Packaging Research Review” highlighting significant growth and advances in the sustainable packaging, healthcare packaging, and sustainable plastic packaging markets. …
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
July 3, 2025
DALLAS, July 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the …
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
July 3, 2025
SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to …
Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change
GlobeNewswire
·
July 3, 2025
IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair …
Complicated Urinary Tract Infections Market Set to Experience Stunning Growth During the Forecast Period (2025–2034) | DelveInsight
GlobeNewswire
·
July 3, 2025
New York, USA, July 03, 2025 (GLOBE NEWSWIRE) -- Complicated Urinary Tract Infections Market Set to Experience Stunning Growth During the Forecast Period (2025–2034) | DelveInsight The growth of the complicated urinary tract infections market is expected …
MESA LABS DECLARES QUARTERLY DIVIDEND
GlobeNewswire
·
July 3, 2025
LAKEWOOD, Colo., July 03, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The …
CapsoVision Announces Closing of Initial Public Offering
GlobeNewswire
·
July 3, 2025
SARATOGA, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy …
AAMI Aligns With National Academy of Medicine AI Code of Conduct
GlobeNewswire
·
July 3, 2025
Arlington, VA, July 03, 2025 (GLOBE NEWSWIRE) -- The Association for the Advancement of Medical Instrumentation (AAMI) today announces its alignment with the National Academy of Medicine’s (NAM) recently published AI Code of Conduct (AICC). AAMI intends to …
Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center
GlobeNewswire
·
July 3, 2025
Vancouver, Canada, July 03, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to …